Logo image of SAVA

CASSAVA SCIENCES INC (SAVA) Stock Fundamental Analysis

USA - NASDAQ:SAVA - US14817C1071 - Common Stock

4.945 USD
+0.31 (+6.57%)
Last: 10/16/2025, 9:39:08 AM
Fundamental Rating

2

Taking everything into account, SAVA scores 2 out of 10 in our fundamental rating. SAVA was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of SAVA is average, but there are quite some concerns on its profitability. SAVA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SAVA had negative earnings in the past year.
SAVA had a negative operating cash flow in the past year.
In the past 5 years SAVA always reported negative net income.
SAVA had a negative operating cash flow in each of the past 5 years.
SAVA Yearly Net Income VS EBIT VS OCF VS FCFSAVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -90.98%, SAVA is not doing good in the industry: 75.38% of the companies in the same industry are doing better.
The Return On Equity of SAVA (-140.01%) is worse than 66.67% of its industry peers.
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROIC N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
SAVA Yearly ROA, ROE, ROICSAVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SAVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SAVA Yearly Profit, Operating, Gross MarginsSAVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SAVA has been increased compared to 1 year ago.
The number of shares outstanding for SAVA has been increased compared to 5 years ago.
There is no outstanding debt for SAVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SAVA Yearly Shares OutstandingSAVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SAVA Yearly Total Debt VS Total AssetsSAVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SAVA has an Altman-Z score of -4.62. This is a bad value and indicates that SAVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SAVA (-4.62) is comparable to the rest of the industry.
There is no outstanding debt for SAVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.62
ROIC/WACCN/A
WACCN/A
SAVA Yearly LT Debt VS Equity VS FCFSAVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.43 indicates that SAVA has no problem at all paying its short term obligations.
SAVA has a Current ratio of 2.43. This is comparable to the rest of the industry: SAVA outperforms 45.13% of its industry peers.
SAVA has a Quick Ratio of 2.43. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
SAVA has a Quick ratio (2.43) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
SAVA Yearly Current Assets VS Current LiabilitesSAVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SAVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.50%, which is quite impressive.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SAVA will show a very strong growth in Earnings Per Share. The EPS will grow by 102.72% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.31%
EPS Next 2Y43.89%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SAVA Yearly Revenue VS EstimatesSAVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 200M 400M 600M 800M 1B
SAVA Yearly EPS VS EstimatesSAVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6 8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 48.48, the valuation of SAVA can be described as expensive.
Based on the Price/Forward Earnings ratio, SAVA is valued a bit cheaper than the industry average as 68.21% of the companies are valued more expensively.
SAVA is valuated expensively when we compare the Price/Forward Earnings ratio to 23.04, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 48.48
SAVA Price Earnings VS Forward Price EarningsSAVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAVA Per share dataSAVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SAVA's earnings are expected to grow with 102.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.89%
EPS Next 3Y102.72%

More info and screens

0

5. Dividend

5.1 Amount

SAVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASSAVA SCIENCES INC

NASDAQ:SAVA (10/16/2025, 9:39:08 AM)

4.945

+0.31 (+6.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-30 2025-07-30
Earnings (Next)11-05 2025-11-05
Inst Owners25.22%
Inst Owner Change0%
Ins Owners5.73%
Ins Owner Change0.76%
Market Cap238.89M
Analysts43.33
Price Target2.04 (-58.75%)
Short Float %13.98%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 48.48
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.72
P/tB 2.72
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)0.1
Fwd EY2.06%
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -4.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
EPS Next Y61.31%
EPS Next 2Y43.89%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.94%
OCF growth 3YN/A
OCF growth 5YN/A